swarupa mitra

Dr. swarupa mitra


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
JJJiten Jaipuria
Jiten Jaipuria
TKTarun Kohli
Tarun Kohli
MVManikandan Venkatasubramaniyan
Manikandan Venkatasubramaniyan
ASAmitabh Singh
Amitabh Singh
SGShashikant Gupta
Shashikant Gupta
SRSudhir Kumar Rawal
Sudhir Kumar Rawal

20 November 2020 in British Journal of Radiology
Verified
Journal Article
Open access
ADAbhinav Dewan
Abhinav Dewan
SMswarupa mitra
swarupa mitra
SASumeet Aggarwal
Sumeet Aggarwal
SBSoumitra Barik
Soumitra Barik
IKInderjeet Kaur
Inderjeet Kaur
RDRupali Dewan
Rupali Dewan
COVID-19 pandemic has had a catastrophic impact on the society, economy and heath-care system all over the globe with virus showing no signs of losing potency. As the situation appears to worsen, extra burden on other specialities like oncology seems to increase. Specific recommendations are necessary for management of cervical cancer in the current context. All concerned specialities must work together in the best interest of the patient. Attempts should be made at managing cervical cancer while limiting the viral spread among the patients and health-care workers without the loss of opportunity. Surgical intervention for early cervical cancer should be postponed or alternative modalities be considered. In a locally advanced disease, concurrent chemoradiation is the treatment of choice. In addition, the following under mentioned suggestions aim to discuss ways of minimizing infection spread, workload rationalization and providing guidance for management of cervical cancer in the presence of COVID-19 infection.

1 September 2017 in International Journal of Particle Therapy
Verified
Journal Article
Open access
MSManoj K. Sharma
Manoj K. Sharma
EHEugen B. Hug
Eugen B. Hug
MBManindra Bhushan
Manindra Bhushan
DMDennis Mah
Dennis Mah
DMDominic Maes
Dominic Maes
SMswarupa mitra
swarupa mitra
Purpose: Brachytherapy is essential for local treatment in cervical carcinoma, but some patients are not suitable for it. Presently, for these patients, the authors prefer a boost by using intensity-modulated radiation therapy (IMRT). The authors evaluated the dosimetric comparison of proton-modulated radiation therapy versus IMRT and volumetric-modulated arc therapy (VMAT) as a boost to know whether protons can replace photons. Patients and Methods: Five patients who received external beam radiation therapy to the pelvis by IMRT were reviewed. Three different plans were made, including pencil beam scanning (PBS), IMRT, and VMAT. The prescribed planning target volume (PTV) was 20 Gy in 4 fractions. The dose to 95% PTV (D95%), the conformity index, and the homogeneity index were evaluated for PTV. The Dmax, D2cc, and Dmean were evaluated for organs at risk along with the integral dose of normal tissue and organs at risk. Results: The PTV coverage was optimal and homogeneous with modulated protons ...

1 October 2014 in Rare Tumors
Verified
Journal Article
Open access
PDF file
SMswarupa mitra
swarupa mitra
AMAnurag Mehta
Anurag Mehta
SGSunil Kumar Gupta
Sunil Kumar Gupta
ASAnila Sharma
Anila Sharma
ALA. Robert Louis
A. Robert Louis
ADAbhinav Dewan
Abhinav Dewan
The primary gastrointestinal non-Hodgkin's lymphoma, although rare, is among the most common extra-nodal lymphomas, considering that gastric lymphomas are more common than intestinal lymphomas. Burkitt's lymphoma (BL) is an aggressive form of B-cell lymphoma that is typically endemic in Africa, while non-endemic cases are found in the rest of the world. Primary gastric BL is extremely rare and only around 50 cases have been reported worldwide. Here we present the case of a young HIV-negative male, who was referred to our department with a stage IV gastric BL. He was planned for palliative chemotherapy, but after the first cycle of chemotherapy he succumbed to the progression of the disease.

3 March 2021 in Cancer Reports
Verified
Journal Article
Open access
PDF file
SBSoumitra Barik
Soumitra Barik
SMswarupa mitra
swarupa mitra
MSMoushumi Suryavanshi
Moushumi Suryavanshi
ADAbhinav Dewan
Abhinav Dewan
IKInderjeet Kaur
Inderjeet Kaur
GVGayatri Vishwakarma
Gayatri Vishwakarma
Background: Concurrent chemoradiotherapy followed by brachytherapy is the standard of care in locally advanced carcinoma cervix. There is no prognostic factor at present to predict the outcome of disease in locally advanced carcinoma cervix.Aim: Differential expression of microRNAs can be used as biomarkers to predict clinical response in locally advanced carcinoma cervix patients.Methods: Thirty‐two patients of locally advanced carcinoma cervix with International Federation of Gynecology and Obstetrics Stage IB‐IVA were enrolled from 2017 to 2018. Expression of microRNA‐9 5p, ‐31 3p, ‐100 5p, ‐125a 5p, ‐125b‐5p, and –200a 5p in formalin‐fixed paraffin embedded (FFPE) biopsied tissue were analyzed by real time quantitative reverse transcriptase polymerase chain reaction (RT qPCR). Pretreatment evaluation was done with clinical examination and MRI pelvis. All patients received concurrent chemoradiotherapy followed by brachytherapy. Patients were evaluated for the clinical response after 3 months of treatment, with clinical examination and MRI pelvis scan using RECIST 1.1 criteria. Patients with no residual disease were classified as Complete responders (CR) and with residual or progressive disease were classified as Nonresponders (NR). Results were statistically analyzed using Mann Whiney U test to examine significant difference between the expression of microRNA between complete responders (CR) and nonresponders (NR).Results: microRNA‐100 5p was upregulated in complete responders (CR) which showed a trend towards statistical significance (p value = 0.05).Conclusion: microRNA‐100 5p can serve as a potential molecular biomarker in predicting clinical response to chemoradiation in locally advanced Carcinoma cervix. Its role should be further investigated in a larger study population.

12 June 2019 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
SASumeet Aggarwal
Sumeet Aggarwal
SMswarupa mitra
swarupa mitra
ADAbhinav Dewan
Abhinav Dewan
GDGarima Durga
Garima Durga
Carcinosarcoma is a rare histological event in the history of prostatic malignancies. Historically aggressive tumours with dismal outcomes reported in scarce literature available so far. Very few recent studies suggest good outcomes with modern era surgery and radiotherapy techniques in localised disease. The case presented here had no history of known risk factors like prior adenocarcinoma or prior radiation therapy. This case presented with obstructive urinary symptoms with no prostate-specific antigen elevation, diagnosed with imaging, managed aggressively with robotic surgery. Detailed immunohistochemistry and pathological review suggested diagnosis as carcinosarcoma with osteosarcomatous differentiation. Very rare such cases were reported in the past with complete clinical, radiological, pathological details and managed aggressively with good outcomes. The patient is disease free after 6 months of follow-up.